Literature DB >> 9677010

Epstein-Barr virus infections and their association with human malignancies: some key questions.

B E Griffin1, S A Xue.   

Abstract

Epstein-Barr virus (EBV) expresses genes that stimulate cells to divide in culture. This property, coupled with the close association of the virus with numerous malignancies, has prompted its designation as a human DNA tumour virus. Before human herpesvirus 8 (HHV-8, alternatively KS virus) was discovered, EBV was unique in this property among the human herpesviruses. EBV infection has been best characterised in terms of gene expression in B lymphocytes and epithelium, which represent cells found in the best known of the associated malignancies, Burkitt's lymphoma and poorly differentiated nasopharyngeal carcinoma. The bulk of evidence supports B cells as the primary EBV reservoir with the viral route into other cell types remaining ill-defined. Molecular studies on gene expression in the associated tumours suggest that EBV encodes a number of functions associated with cell growth; whether they are expressed or silent may largely be under control of the host cell. Many questions partly addressed here remain with regard to this virus, two critical ones relating to the mechanisms by which viral gene products escape T-cell recognition - relevant from the fact that gene expression is not tightly restricted to nonimmunogenic functions in tumours - and whether EBV can invoke cell growth in a manner not requiring its continued presence. The latter seems a plausible hypothesis and is of particular importance with regard to identifying and understanding pathologies associated with EBV, as viral transcriptional transactivators may on initial infection permanently perturb cell regulation.

Entities:  

Mesh:

Year:  1998        PMID: 9677010     DOI: 10.3109/07853899809005852

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  6 in total

1.  Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus.

Authors:  P R Smith; O de Jesus; D Turner; M Hollyoake; C E Karstegl; B E Griffin; L Karran; Y Wang; S D Hayward; P J Farrell
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Expression of two related viral early genes in Epstein-Barr virus-associated tumors.

Authors:  S A Xue; Q L Lu; R Poulsom; L Karran; M D Jones; B E Griffin
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.

Authors:  Amolo S Asito; Erwan Piriou; Peter Sumba Odada; Nancy Fiore; Jaap M Middeldorp; Carole Long; Sheetij Dutta; David E Lanar; Walter G Jura; Collins Ouma; Juliana A Otieno; Ann M Moormann; Rosemary Rochford
Journal:  Infect Agent Cancer       Date:  2010-07-28       Impact factor: 2.965

4.  A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC).

Authors:  G Aurilio; V Ricci; F De Vita; M Fasano; N Fazio; M Orditura; L Funicelli; G De Luca; D Iasevoli; F Iovino; F Ciardiello; G Conzo; F Nolè; Mg Lamendola
Journal:  Ecancermedicalscience       Date:  2010-12-22

5.  Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR.

Authors:  R Serene Perkins; Katherine Sahm; Cindy Marando; Diana Dickson-Witmer; Gregory R Pahnke; Mark Mitchell; Nicholas J Petrelli; Irving M Berkowitz; Patricia Soteropoulos; Virginie M Aris; Stephen P Dunn; Leslie J Krueger
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

6.  Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.

Authors:  Mieko Toyoda; Bong-Ha Shin; Shili Ge; James Mirocha; David Thomas; Maggie Chu; Edgar Rodriguez; Christine Chao; Anna Petrosyan; Odette A Galera; Ashley Vo; Jua Choi; Alice Peng; Joseph Kahwaji; Stanley C Jordan
Journal:  J Immunol Res       Date:  2017-02-06       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.